6533b82ffe1ef96bd1295e1e
RESEARCH PRODUCT
Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.
Fabio Salvatore MacalusoAntonio CraxìVincenza Calvarusosubject
Microbiology (medical)OncologyLiver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularbusiness.industryLiver NeoplasmsHcv clearanceAlcohol abuseHepatitis C Chronicmedicine.diseaseMicrobiologyVirologyRisk AssessmentResidual riskLiver diseaseInsulin resistanceHepatocellular carcinomaInternal medicineDiabetes mellitusmedicineHumansHCCbusinessdescription
ABSTRACT Eradication of HCV in patients with advanced liver fibrosis or cirrhosis reduces, but does not altogether abolish, the risk of development of hepatocellular carcinoma. The reasons underlying this residual risk remain elusive. Even if HCV clearance eliminates its direct and indirect carcinogenic effects, the persistence of cirrhosis and the possible coexistence of metabolic factors (diabetes, obesity and insulin resistance) and of alcohol abuse can promote the development of hepatocellular carcinoma acting as autonomous, nonviral carcinogenic factors. Lessons learned in the IFN era may still assist in predicting the forthcoming scenario, when IFN-free regimens will obtain high rates of viral clearance even at the most advanced stages of liver disease.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-01 |